• 1.

    Stanley SL Jr., 2003. Amoebiasis. Lancet 361: 10251034.

  • 2.

    Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J, 2007. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 20: 511532.

    • Search Google Scholar
    • Export Citation
  • 3.

    Jackson TF, 1998. Entamoeba histolytica and Entamoeba dispar are distinct species; clinical, epidemiological and serological evidence. Int J Parasitol 28: 181186.

    • Search Google Scholar
    • Export Citation
  • 4.

    Oliveira FM, Neumann E, Gomes MA, Caliari MV, 2015. Entamoeba dispar: could it be pathogenic. Trop Parasitol 5: 914.

  • 5.

    Formenti F, Perandin F, Bonafini S, Degani M, Bisoffi Z, 2015. Evaluation of the new ImmunoCard STAT!® CGE test for the diagnosis of amebiasis [in French]. Bull Soc Pathol Exot 108: 171174.

    • Search Google Scholar
    • Export Citation
  • 6.

    Calderaro A, Gorrini C, Bommezzadri S, Piccolo G, Dettori G, Chezzi C, 2006. Entamoeba histolytica and Entamoeba dispar: comparison of two PCR assays for diagnosis in a non-endemic setting. Trans R Soc Trop Med Hyg 100: 450457.

    • Search Google Scholar
    • Export Citation
  • 7.

    Gatti S et al. 2002. Amebic infections due to the Entamoeba histolytica-Entamoeba dispar complex: a study of the incidence in a remote rural area of Ecuador. Am J Trop Med Hyg 67: 123127.

    • Search Google Scholar
    • Export Citation
  • 8.

    Levecke B, Dreesen L, Barrionuevo-Samaniego M, Benitez Ortiz W, Praet N, Brandt J, Dorny P, 2011. Molecular differentiation of Entamoeba spp. in a rural community of Loja province, south Ecuador. Trans R Soc Trop Med Hyg 105: 737739.

    • Search Google Scholar
    • Export Citation
  • 9.

    Verweij JJ, Oostvogel F, Brienen EA, Nang-Beifubah A, Ziem J, Polderman AM, 2003. Prevalence of Entamoeba histolytica and Entamoeba dispar in northern Ghana. Trop Med Int Health 8: 11531156.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 792 296 35
PDF Downloads 466 134 20
 
 
 
 
 
 
 
 
 
 
 

Use of Real-Time Polymerase Chain Reaction to Differentiate between Pathogenic Entamoeba histolytica and the Nonpathogenic Entamoeba dispar in Ecuador

Ángel GuevaraCarrera de Medicina, Instituto de Biomedicina, Universidad Central, Quito, Ecuador;

Search for other papers by Ángel Guevara in
Current site
Google Scholar
PubMed
Close
,
Yosselin VicuñaCarrera de Medicina, Instituto de Biomedicina, Universidad Central, Quito, Ecuador;

Search for other papers by Yosselin Vicuña in
Current site
Google Scholar
PubMed
Close
,
Denisse CostalesLaboratorio Clinico, Hospital General Docente Calderón MSP, Quito, Ecuador;

Search for other papers by Denisse Costales in
Current site
Google Scholar
PubMed
Close
,
Sandra ViveroCarrera de Medicina, Instituto de Biomedicina, Universidad Central, Quito, Ecuador;

Search for other papers by Sandra Vivero in
Current site
Google Scholar
PubMed
Close
,
Mariella AnselmiCentro de Epidemiología Comunitaria y Medicina Tropical (CECOMET), Esmeraldas, Ecuador;
Centre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy

Search for other papers by Mariella Anselmi in
Current site
Google Scholar
PubMed
Close
,
Zeno BisoffiCentre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy

Search for other papers by Zeno Bisoffi in
Current site
Google Scholar
PubMed
Close
, and
Fabio FormentiCentre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy

Search for other papers by Fabio Formenti in
Current site
Google Scholar
PubMed
Close
View More View Less

Microscopic examination of stool samples has been considered to be the “gold standard” for diagnosis of intestinal parasites. Recently, polymerase chain reaction (PCR) has been approved by the World Health Organization as the method of choice for the diagnosis of Entamoeba histolytica. Of the 106 stool samples collected from the Esmeraldas and Pichincha provinces of Ecuador, all (100%) were positive for E. histolytica/Entamoeba dispar by light microscopy, whereas using real-time PCR (RT-PCR) DNA amplification, 74 (69.8%) were positive for E. dispar and only three (2.8%) were positive for E. histolytica. Some 29 (27.4%) samples were negative for the presence of either E. histolytica or E. dispar, this may be due the presence of Entamoeba mosksvskii, which is morphologically identical to E. histolytica/E. dispar and not specifically targeted by the RT-PCR used. These results indicate the necessity of reevaluating the epidemiology of amebiasis in Ecuador as the prominent species found are nonpathogenic.

Amebiasis is a common intestinal parasitic infection caused by Entamoeba histolytica, approximately 500 million people are estimated to be infected worldwide.1 The prevalence of Entamoeba infection varies being more common in developing countries where poor sanitation leads to ingestion of food or water contaminated with Entamoeba spp. cysts. Generally, infections are asymptomatic but in some cases, colitis and extraintestinal infection can occur.2

The diagnosis of intestinal amebiasis is based on the microscopic examination of stool samples in search of cyst and/or the trophozoite stages of the parasite. At least six different species of the genus Entamoeba can be found in human intestinal lumen; two of them, Entamoeba dispar and Entamoeba moshkovskii, are morphologically identical to E. histolytica, thus making it nigh impossible to differentiate them by microscopy. In addition, E. histolytica is the only recognized pathogenic species, although the potential pathogenicity of E. dispar and E. moshkovskii has not been completely ruled out.3,4 Therefore, new diagnostic techniques are needed to differentiate Entamoeba species; a rapid diagnostic immunochromatographic antigen test to differentiate E. histolytica from the nonpathogenic species exists but has a low specificity for E. histolytica sensu stricto.5 Molecular DNA-based tools have been shown to be useful to differentiate between E. histolytica, E. dispar, and E. moshkovskii.2,6

Previous studies in Ecuador showed a higher prevalence of E. dispar infections in comparison with E. histolytica.7,8 In the present study, 106 samples from patients from the provinces of Esmeraldas (rural area) and Pichincha (urban area) in Ecuador, previously positive for E. histolytica/E. dispar infection by microscopy, were collected to confirm the presence of infection using real-time polymerase chain reaction (RT-PCR).

A portion of the stool sample was prepared for observation by light microscopy in search of intestinal parasites. Another part of the sample, approximately 200 mg, was preserved in phosphate buffered saline/2% polyvinylpolypyrrolidone and frozen at −20°C till DNA extraction using QIAamp® DNA stool kit (Qiagen N.V., Hilden, Germany) according to the manufacturer’s instructions. In each sample, 2 μL of exogenous Phocine Herpesvirus type-1 DNA (PhHV-1) was added as an internal control. The RT-PCR targets have been described previously by Verweij et al.9 Amplification reactions for all the samples were performed in a 25-μL reaction mixture containing PCR buffer (SsoFast master mix; Bio-Rad Laboratories®, Milan, Italy), 2.5 μg of bovine serum albumin (Sigma-Aldrich®, St. Louis, MO), 80 nM of each of the PhHV-1–specific primers, and 200 nM of PhHV-1 CY5-BHQ2 labeled probe, 60 nM of each E. histolytica/E. dispar specific primers, and 200 nM of E. histolytica fluoroscein amidite-minor grove binder–labeled probe and E. dispar 2′-chloro-7′phenyl-1,4-dichloro-6-carboxy-fluorescein-minor grove binder–labeled probe; RT-PCR cycles consisted of 3 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C, and 30 seconds at 72°C. Reactions, detection, and data analyses were performed with the DA7600® RT PCR (DaAn Gene Co. Ltd., Guangzhou, China). Positive and negative controls were included in all the experiments. One of the two positive controls had a low cycle threshold (Ct) (30 < Ct < 36) and the other a high Ct (37 < Ct < 39.9); for all the RT-PCR analysis, the threshold was set at 200.

Using light microscopy, E. histolytica/dispar cysts were observed in all samples along with other intestinal parasites (Table 1). However, using RT-PCR DNA amplification, few stool samples (N = 3 [2.8%]) were positive for E. histolytica (Table 2). Given that the method of light microscopy is the standard laboratory method used for diagnosing amoeba, 97.2% of patients are potentially being misdiagnosed and unnecessarily treated. Because of the lack of molecular diagnostics in rural areas, the attending physician must decide if treatment is necessary based more on clinical evidence than laboratory results. The presence of E. histolytica/dispar cysts in stool samples does not necessarily warrant treatment. In conclusion, a reevaluation of the epidemiology of amebiasis in Ecuador is necessary to minimize these unnecessary treatments for the presence of nonpathogenic species.

Table 1

Intestinal parasites in stool samples examined by light microscopy examination

Eh/d, n (%)Ec, n (%)Ib, n (%)En, n (%)Gl, n (%)Ei, n (%)Enb.i, n (%)Bh, n (%)Tt, n (%)Al, n (%)Sst, n (%)
Rural area, N
7878 (100)53 (67.9)5 (6.4)3 (3.8)11 (14.1)6 (7.6)7 (8.9)4 (5.1)26 (33.3)48 (61.5)4 (5.1)
Urban area, N
2828 (100)11 (39.2)1 (3.5)1 (3.5)3 (10.7)
Total
106106 (100)64 (60.38)6 (5.6)4 (3.8)11 (10.4)6 (5.6)7 (6.6)7 (6.6)26 (24.5)48 (45.2)4 (3.8)

Al = Ascaris lumbricoides; Bh = Blastocystis hominis; Ec = Entamoeba coli; Eh/d = Entamoeba histolytica/dispar; Ei = Entoromonas intestinalis; En = Endolimax nana; Enb.i = Enbadomonas intestinalis; Gl = Giardia lamblia; Ib = Iodamoeba butschlii; Sst = Strongyloides stercolaris; Tt = Trichuris trichiura. In all cases, cysts were observed except eggs for the helminths Al and Tt. In Sst, the parasite stage detected was larva.

Table 2

RT-PCR results

RT-PCREntamoeba histolyticaEntamoeba dispar
n (%)n (%)
Rural area, n
78062 (79.48)
Urban area, n
283 (10.71)12 (42.85)
Total, n
1063 (2.83)74 (69.81)

RT-PCR = real-time polymerase chain reaction.

Acknowledgment:

We thank Ronald Guderian for the critical revision of the manuscript.

REFERENCES

  • 1.

    Stanley SL Jr., 2003. Amoebiasis. Lancet 361: 10251034.

  • 2.

    Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J, 2007. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 20: 511532.

    • Search Google Scholar
    • Export Citation
  • 3.

    Jackson TF, 1998. Entamoeba histolytica and Entamoeba dispar are distinct species; clinical, epidemiological and serological evidence. Int J Parasitol 28: 181186.

    • Search Google Scholar
    • Export Citation
  • 4.

    Oliveira FM, Neumann E, Gomes MA, Caliari MV, 2015. Entamoeba dispar: could it be pathogenic. Trop Parasitol 5: 914.

  • 5.

    Formenti F, Perandin F, Bonafini S, Degani M, Bisoffi Z, 2015. Evaluation of the new ImmunoCard STAT!® CGE test for the diagnosis of amebiasis [in French]. Bull Soc Pathol Exot 108: 171174.

    • Search Google Scholar
    • Export Citation
  • 6.

    Calderaro A, Gorrini C, Bommezzadri S, Piccolo G, Dettori G, Chezzi C, 2006. Entamoeba histolytica and Entamoeba dispar: comparison of two PCR assays for diagnosis in a non-endemic setting. Trans R Soc Trop Med Hyg 100: 450457.

    • Search Google Scholar
    • Export Citation
  • 7.

    Gatti S et al. 2002. Amebic infections due to the Entamoeba histolytica-Entamoeba dispar complex: a study of the incidence in a remote rural area of Ecuador. Am J Trop Med Hyg 67: 123127.

    • Search Google Scholar
    • Export Citation
  • 8.

    Levecke B, Dreesen L, Barrionuevo-Samaniego M, Benitez Ortiz W, Praet N, Brandt J, Dorny P, 2011. Molecular differentiation of Entamoeba spp. in a rural community of Loja province, south Ecuador. Trans R Soc Trop Med Hyg 105: 737739.

    • Search Google Scholar
    • Export Citation
  • 9.

    Verweij JJ, Oostvogel F, Brienen EA, Nang-Beifubah A, Ziem J, Polderman AM, 2003. Prevalence of Entamoeba histolytica and Entamoeba dispar in northern Ghana. Trop Med Int Health 8: 11531156.

    • Search Google Scholar
    • Export Citation

Author Notes

Address correspondence to Ángel Guevara, Carrera de Medicina, Instituto de Biomedicina, Universidad Central del Ecuador, Iquique N14-121 y Sodiro–Itchimbía, Sector El Dorado, Quito, Ecuador. E-mail: agguevara @uce.edu.ec

Financial support: CECOMET, Esmeraldas, Ecuador, and Centre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Verona), Italy.

Authors’ addresses: Ángel Guevara, Yosselin Vicuña, and Sandra Vivero, Carrera de Medicina, Instituto de Biomedicina, Universidad Central del Ecuador, Quito, Ecuador, E-mails: agguevara@uce.edu.ec, yavicuna@uce.edu.ec, and sgviverog@uce.edu.ec. Denisse Costales, Laboratorio Clinico, Hospital General Docente Calderón MSP, Quito, Ecuador, E-mail: denissempc@hotmail.com. Mariella Anselmi, Centro de Epidemiología Comunitaria y Medicina Tropical (CECOMET), Esmeraldas, Ecuador, E-mail: mariella.anselmi@alice.it. Zeno Bisoffi and Fabio Formenti, Centre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy, E-mails: zeno.bisoffi@sacrocuore.it and fabio.formenti@sacrocuore.it.

Save